Agios Pharmaceuticals, Inc. $AGIO Shares Sold by Edgestream Partners L.P.

Posted by Brenda Bartman on Aug 1st, 2026

Edgestream Partners L.P. trimmed its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 14.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 143,731 shares of the biopharmaceutical company’s stock after selling 24,267 shares during the period. Edgestream Partners L.P. owned about 0.24% of Agios Pharmaceuticals worth $4,862,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of AGIO. Creative Planning grew its holdings in Agios Pharmaceuticals by 2.2% during the third quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company’s stock worth $527,000 after acquiring an additional 280 shares during the period. Assetmark Inc. lifted its holdings in Agios Pharmaceuticals by 37.9% in the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 362 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Agios Pharmaceuticals by 0.4% in the second quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company’s stock valued at $4,393,000 after acquiring an additional 512 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Agios Pharmaceuticals by 26.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 588 shares during the period. Finally, CANADA LIFE ASSURANCE Co boosted its position in shares of Agios Pharmaceuticals by 3.4% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company’s stock worth $796,000 after purchasing an additional 662 shares in the last quarter.

Agios Pharmaceuticals Stock Performance

AGIO opened at $30.02 on Friday. The business’s fifty day moving average is $34.48 and its two-hundred day moving average is $30.88. The company has a market cap of $1.79 billion, a price-to-earnings ratio of -4.28 and a beta of 0.54. Agios Pharmaceuticals, Inc. has a one year low of $22.24 and a one year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The firm had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 34.40%. On average, analysts predict that Agios Pharmaceuticals, Inc. will post -6.33 EPS for the current fiscal year.

Agios Pharmaceuticals News Roundup

Here are the key news stories impacting Agios Pharmaceuticals this week:

Positive Sentiment: Second-quarter revenue from mitapivat products Pyrukynd and Aqvesme rose to $44.7 million from $12.5 million a year earlier, helped by Aqvesme’s U.S. launch in thalassemia. The company reported 442 cumulative prescriptions as of June 30. Agios second-quarter financial results
Positive Sentiment: Agios reported a narrower quarterly loss than the Zacks consensus estimate, while management highlighted continued development of its hematology pipeline. The company also has $964.8 million in cash, cash equivalents and marketable securities to fund commercialization and research programs. Agios Q2 earnings report
Positive Sentiment: The FDA granted priority review to mitapivat’s supplemental application in sickle cell disease, with a November 1, 2026 decision date. Approval could expand the drug’s addressable market. Agios also expects $45 million to $50 million in 2026 revenue from pyruvate kinase deficiency. Agios revenue outlook and sickle cell review
Neutral Sentiment: HC Wainwright maintained a Buy rating and a $55 price objective while slightly raising its long-term 2030 EPS forecast. The forecast change supports the longer-term outlook but has limited immediate impact. Agios analyst estimates
Negative Sentiment: Agios remains deeply unprofitable. Its reported quarterly loss of $1.69 per share was slightly worse than one analyst consensus estimate of $1.65, underscoring continued earnings risk despite revenue growth. Agios earnings results
Negative Sentiment: Truist lowered its price target from $41 to $39, although it retained a Buy rating. Separately, Pomerantz announced an investigation into potential investor claims, creating an additional headline and legal overhang. Truist price target update

Wall Street Analyst Weigh In

AGIO has been the topic of a number of recent analyst reports. Royal Bank Of Canada upped their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. Bank of America raised their price objective on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. HC Wainwright boosted their price objective on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a report on Thursday. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Citigroup increased their target price on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a report on Friday. Five research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $40.88.

Read Our Latest Stock Report on Agios Pharmaceuticals

About Agios Pharmaceuticals

(Free Report)

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.